keyword
MENU ▼
Read by QxMD icon Read
search

Genesight

keyword
https://www.readbyqxmd.com/read/28515818/pharmacogenomic-testing-for-psychotropic-medication-selection-a-systematic-review-of-the-assurex-genesight-psychotropic-test
#1
(no author information available yet)
BACKGROUND: A large proportion of the Ontario population lives with a diagnosed mental illness. Nearly 5% of Ontarians have major depressive disorder, and another 5% have another type of depressive disorder, bipolar disorder, schizophrenia, anxiety, or some other disorder not otherwise specified. Medications are commonly used to treat mental illness, but choosing the right medication for each patient is challenging, and more than 40% of patients discontinue their medication within 90 days because of adverse effects or lack of response...
2017: Ontario Health Technology Assessment Series
https://www.readbyqxmd.com/read/28456840/rapid-evidence-review-of-the-comparative-effectiveness-harms-and-cost-effectiveness-of-pharmacogenomics-guided-antidepressant-treatment-versus-usual-care-for-major-depressive-disorder
#2
REVIEW
Kimberly Peterson, Eric Dieperink, Johanna Anderson, Erin Boundy, Lauren Ferguson, Mark Helfand
OBJECTIVE: This study aims to conduct an evidence review of the effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment for major depressive disorder. METHODS: We searched MEDLINE®, the Cochrane Central Registry of Controlled Trials, and PsycINFO through February 2017. We used prespecified criteria to select studies, abstract data, and rate internal validity and strength of the evidence (PROSPERO number CRD42016036358). RESULTS: We included two randomized trials (RCT), five controlled cohort studies, and six modeling studies of mostly women in their mid-40s with few comorbidities...
June 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28238356/economic-utility-combinatorial-pharmacogenomics-and-medication-cost-savings-for-mental-health-care-in-a-primary-care-setting
#3
Lisa C Brown, Raymond A Lorenz, James Li, Bryan M Dechairo
PURPOSE: This study was an analysis based on a previously completed prospective study investigating medication costs of patients with mental illness guided by using the GeneSight proprietary combinatorial pharmacogenomic (PGx) test. The primary objective of this study was to determine potential cost savings of combinatorial PGx testing over the course of 1 year in patients with mental illness treated by primary care providers (PCPs) and psychiatrists who had switched or added a new psychiatric medication after patients failed to respond to monotherapy...
February 18, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28068459/does-pharmacogenomic-testing-improve-clinical-outcomes-for-major-depressive-disorder-a-systematic-review-of-clinical-trials-and-cost-effectiveness-studies
#4
REVIEW
Joshua D Rosenblat, Yena Lee, Roger S McIntyre
OBJECTIVE: Pharmacogenomic testing has become scalable and available to the general public. Pharmacogenomics has shown promise for predicting antidepressant response and tolerability in the treatment of major depressive disorder (MDD). In theory, pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. The current systematic review examines the extant literature to determine the impact of pharmacogenomic testing on clinical outcomes in MDD and assesses its cost-effectiveness...
June 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27606312/clinical-utility-of-combinatorial-pharmacogenomics-guided-antidepressant-therapy-evidence-from-three-clinical-studies
#5
C Anthony Altar, Joseph Carhart, Josiah D Allen, Daniel Hall-Flavin, Joel Winner, Bryan Dechairo
DNA of 258 patients with treatment-resistant depression was collected in three 8-10 week, two-arm, prospective clinical trials. Forty-four allelic variations were measured in genes for the cytochrome P450 (CYP) enzymes CYP2D6, CYPC19, and CYP1A2, the serotonin transporter (SLC6A4), and the 5-HT2A receptor (HTR2A). The combinatorial pharmacogenomic (CPGx™) GeneSight test results were provided to clinicians to support medication changes from baseline (guided arm), or they were provided at the end of each study to clinicians of unguided patients who were treated as usual (TAU)...
October 2015: Molecular Neuropsychiatry
https://www.readbyqxmd.com/read/26086890/combinatorial-pharmacogenomic-guidance-for-psychiatric-medications-reduces-overall-pharmacy-costs-in-a-1-year-prospective-evaluation
#6
Joel G Winner, Joseph M Carhart, C Anthony Altar, Seth Goldfarb, Josiah D Allen, Gabriela Lavezzari, Kelly K Parsons, Andrew G Marshak, Susan Garavaglia, Bryan M Dechairo
OBJECTIVES: The objective of this project was to determine pharmacy cost savings and improvement in adherence based on a combinatorial pharmacogenomic test (CPGx ) in patients who had switched or added a new psychiatric medication after having failed monotherapy for their psychiatric disorder. RESEARCH DESIGN AND METHODS: The prospective project compared 1 year pharmacy claims between a GeneSight CPGx guided cohort and a propensity-matched control group. Patients were project eligible if they augmented or switched to a different antidepressant or antipsychotic medication within the previous 90 days...
2015: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/25686762/clinical-validity-combinatorial-pharmacogenomics-predicts-antidepressant-responses-and-healthcare-utilizations-better-than-single-gene-phenotypes
#7
C A Altar, J M Carhart, J D Allen, D K Hall-Flavin, B M Dechairo, J G Winner
In four previous studies, a combinatorial multigene pharmacogenomic test (GeneSight) predicted those patients whose antidepressant treatment for major depressive disorder resulted in poorer efficacy and increased health-care resource utilizations. Here, we extended the analysis of clinical validity to the combined data from these studies. We also compared the outcome predictions of the combinatorial use of allelic variations in genes for four cytochrome P450 (CYP) enzymes (CYP2D6, CYP2C19, CYP2C9 and CYP1A2), the serotonin transporter (SLC6A4) and serotonin 2A receptor (HTR2A) with the outcome predictions for the very same subjects using traditional, single-gene analysis...
October 2015: Pharmacogenomics Journal
https://www.readbyqxmd.com/read/25375387/pharmacogenetic-testing-in-psychiatry-not-quite-ready-for-primetime
#8
REVIEW
Robert H Howland
To the extent that genetic factors are associated with the efficacy, tolerability, and safety of different drugs, pharmacogenetic tests may be used to personalize medication treatments for an individual. Pharmacogenetic tests, such as GeneSight Psychotropic and the Genecept Assay, are being marketed directly to patients and prescribers despite a relative lack of evidence to support their clinical validity or utility. Pharmacogenetic testing is potentially useful in certain clinical situations, but its usefulness will depend on the knowledge base of the prescriber to be able to interpret the findings for a particular patient...
November 2014: Journal of Psychosocial Nursing and Mental Health Services
https://www.readbyqxmd.com/read/24533704/third-clinical-trial-reinforces-the-use-of-the-genesight%C3%A2-pharmacogenomic-test
#9
Theo Bond
No abstract text is available yet for this article.
February 2014: Pharmacogenomics
https://www.readbyqxmd.com/read/24229738/a-prospective-randomized-double-blind-study-assessing-the-clinical-impact-of-integrated-pharmacogenomic-testing-for-major-depressive-disorder
#10
RANDOMIZED CONTROLLED TRIAL
Joel G Winner, Joseph M Carhart, C Anthony Altar, Josiah D Allen, Bryan M Dechairo
OBJECTIVE: A prospective double-blind randomized control trial (RCT) to evaluate the benefit of a combinatorial, five gene pharmacogenomic test and interpretive report (GeneSight) for the management of psychotropic medications used in the treatment of major depression in an outpatient psychiatric practice. METHODS: Depressed adult outpatients were randomized to a treatment as usual (TAU, n=25) arm or a pharmacogenomic-informed GeneSight (n=26) arm. Subjects were blinded to their treatment group and depression severity was assessed by blinded study raters...
November 2013: Discovery Medicine
https://www.readbyqxmd.com/read/24018772/utility-of-integrated-pharmacogenomic-testing-to-support-the-treatment-of-major-depressive-disorder-in-a-psychiatric-outpatient-setting
#11
Daniel K Hall-Flavin, Joel G Winner, Josiah D Allen, Joseph M Carhart, Brian Proctor, Karen A Snyder, Maureen S Drews, Linda L Eisterhold, Jennifer Geske, David A Mrazek
OBJECTIVE: The objective was to evaluate the potential benefit of an integrated, five-gene pharmacogenomic test and interpretive report (GeneSight) for the management of psychotropic medications used to treat major depression in an outpatient psychiatric practice. METHODS: The open-label study was divided into two groups. In the first (unguided) group (n = 113), pharmacogenomic information was not shared until all participants completed the study. In the second (guided) group (n = 114), the pharmacogenomic report was provided to physicians for clinical use...
October 2013: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/19787079/image-analysis-and-data-normalization-procedures-are-crucial-for-microarray-analyses
#12
Ali Kpatcha Kadanga, Christine Leroux, Muriel Bonnet, Stéphanie Chauvet, Bruno Meunier, Isabelle Cassar-Malek, Jean-François Hocquette
This study was conducted with the aim of optimizing the experimental design of array experiments. We compared two image analysis and normalization procedures prior to data analysis using two experimental designs. For this, RNA samples from Charolais steers Longissimus thoracis muscle and subcutaneous adipose tissues were labeled and hybridized to a bovine 8,400 oligochip either in triplicate or in a dye-swap design. Image analysis and normalization were processed by either GenePix/MadScan or ImaGene/GeneSight...
March 17, 2008: Gene Regulation and Systems Biology
https://www.readbyqxmd.com/read/18199711/full-term-pregnancy-induces-a-specific-genomic-signature-in-the-human-breast
#13
COMPARATIVE STUDY
Jose Russo, Gabriela A Balogh, Irma H Russo
Breast cancer risk has traditionally been linked to nulliparity or late first full-term pregnancy, whereas young age at first childbirth, multiparity, and breast-feeding are associated with a reduced risk. Early pregnancy confers protection by inducing breast differentiation, which imprints a specific and permanent genomic signature in experimental rodent models. For testing whether the same phenomenon was detectable in the atrophic breast of postmenopausal parous women, we designed a case-control study for the analysis of the gene expression profile of RNA extracted from epithelial cells microdissected from normal breast tissues obtained from 18 parous and 7 nulliparous women free of breast pathology (controls), and 41 parous and 8 nulliparous women with history of breast cancer (cases)...
January 2008: Cancer Epidemiology, Biomarkers & Prevention
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"